The efficacy of Alecensa (alectinib) in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer, who were identified using liquid biopsy in the phase II/III BFAST study, is consistent with efficacy in those identified by tissue analysis in the phase III ALEX study.
Tecentriq plus chemotherapy showed a statistically significant improvement in progression-free survival compared with platinum-based chemotherapy alone for the first-line initial treatment of patients with previously untreated locally advanced or metastatic urothelial carcinoma (mUC) eligible and ineligible for cisplatin chemotherapy.
Results from the phase III BEACON CRC trial show significant improvements in overall survival and objective response rates for the BRAFTOVI Triplet and BRAFTOVI Doublet combination (BRAFTOVI and cetuximab), compared to cetuximab plus irinotecan-containing regimens (Control), and provide analysis of the efficacy and safety of the BRAFTOVI Triplet compared to the BRAFTOVI Doublet.
Combination therapy with mavorixafor and axitinib (Inlyta) demonstrated clinical improvement with encouraging median progression free survival in a heavily pretreated advanced clear cell renal cell carcinoma patient population.
Comprehensive tobacco treatment can help cancer patients quit and abstain from smoking, according to a study from MD Anderson Cancer Center.
Lynparza (olaparib) demonstrated statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival in certain tumors.
Barry Kramer, former director of the NCI Division of Cancer Prevention, has received the People's Republic of China Friendship Award, the highest honor given to non-citizens.
Moffitt Cancer Center has formed a contract research organization to accelerate the institution's immunotherapy research.
We asked six experts in disease prevention, nutrition, and guidelinemaking to discuss the just-published recommendations that disagree with the dietary guidelines promulgated by mainstream health organizations.
The senior author of the recent recommendation that disagrees with the dietary guidelines promulgated by mainstream health organizations said there is low-certainty evidence of increased risk of cancer, heart disease, and other harm from eating red meat and processed meat.
